BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.

Item

http://www.wikidata.org/entity/Q46127672

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

BU and CY as conditioning regi ...... atients with multiple myeloma.

@en

BU and CY as conditioning regi ...... atients with multiple myeloma.

@nl

type

Item

label

BU and CY as conditioning regi ...... atients with multiple myeloma.

@en

BU and CY as conditioning regi ...... atients with multiple myeloma.

@nl

prefLabel

BU and CY as conditioning regi ...... atients with multiple myeloma.

@en

BU and CY as conditioning regi ...... atients with multiple myeloma.

@nl

P1476

BU and CY as conditioning regi ...... atients with multiple myeloma.

@en

P2093

C W Ehmann

http://www.w3.org/2001/XMLSchema#string

D F Claxton

http://www.w3.org/2001/XMLSchema#string

D W Dougherty

http://www.w3.org/2001/XMLSchema#string

G Talamo

http://www.w3.org/2001/XMLSchema#string

J J Drabick

http://www.w3.org/2001/XMLSchema#string

J Sivik

http://www.w3.org/2001/XMLSchema#string

W Rybka

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.

Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.

Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.

P2888

bmt.2008.446

P304

157-161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2008.446

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23995137

http://www.w3.org/2001/XMLSchema#string

P6179

1034133494

http://www.w3.org/2001/XMLSchema#string

P698

19204716

http://www.w3.org/2001/XMLSchema#string